The U.S. Food and Drug Administration granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral t...
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus A...
Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles...
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Sanofi announced that the Europ...
In the Annex 1 era, media fills must replicate the routine aseptic manufacturing process as closely as possible. This includes all critical manufacturing s...
Curium™ announced it is advancing plans for a second cyclotron investment in Romania, reaffirming the company’s long-term commitment to expan...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Sanofi announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis ...
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology tha...
Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 rece...
The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...
A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...
arcoris bio, a Swiss life science research tools and in vitro diagnostics company, announced a distribution partnership with Europa Biosite, a leading di...
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding ...
© 2026 Biopharma Boardroom. All Rights Reserved.
